1st Circ. Revives Investors' Feraheme Risks Class Action
The First Circuit on Monday revived a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks associated with iron deficiency treatment Feraheme, ruling...To view the full article, register now.
Already a subscriber? Click here to view full article